Quantbot Technologies LP Altimmune, Inc. Transaction History

Quantbot Technologies LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$2.4 - $3.45 $36,720 - $52,785	15,300 New	15,300 $39,000
Q1 2023 May 12, 2023	SELL	$4.19 - $16.83 $48,260 - $193,847	-11,518 Reduced 84.72%	2,077 $8,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $78,161 - $147,112	-8,943 Reduced 39.68%	13,595 $223,000
Q3 2022 Nov 07, 2022	BUY	$10.67 - $22.41 $240,480 - $505,076	22,538 New	22,538 $287,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.